Iniparib是一种不可逆的PARP-1抑制剂，有抗肿瘤活性。Iniparib是4-iodo-3-nitrosobenzamide的药物前体，4-iodo-3-nitrosobenzamide通过与PARP1的第一个锌指结构结合，抑制PARP1活性。

参考文献

[1] Mendeleyev J, Kirsten E, Hakam A, et al. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem Pharmacol. 1995 Aug 25;50(5):705-14. doi: 10.1016/0006-2952(95)00189-7(IF:4.825).

[2] Bauer PI, Mendeleyeva J, Kirsten E, et, al. Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease. Biochem Pharmacol. 2002 Feb 1;63(3):455-62. doi: 10.1016/s0006-2952(01)00872-3(IF:4.825).

[3] Liu X, Shi Y, Maag DX, et, al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012 Jan 15;18(2):510-23. doi: 10.1158/1078-0432.CCR-11-1973(IF:8.911).

-25~-15℃保存，有效期3年。